Cancer Family
Malignant Bone Marrow Neoplasm
CI-CAN-00000226Explore in graph →
1,035 active trials28 approved drugs633 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000226Explore in graph →
Clinical trials
4,612 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (801)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00602225 | Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 50 | University of WashingtonOTHER | 1 | Mar 9, 2018 | clinicaltrials |
| NCT01842139 | Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission | completed | Phase 1 | 7 | University of ChicagoOTHER | 1 | Mar 9, 2018 | clinicaltrials |
| NCT01193699 | Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera(PEGINVERA) | completed | Phase 1 / Phase 2 | 24 | AOP Orphan Pharmaceuticals AGINDUSTRY | 1 | Jan 30, 2018 | clinicaltrials |
| NCT00875693 | A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning (RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT) for Primary Refractory and Relapsed Acute Myelogenous Leukemia (AML) | completed | Phase 1 | 47 | Weill Medical College of Cornell UniversityOTHER | 1 | Jan 17, 2018 | clinicaltrials |
| NCT00908167 | Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies | completed | Phase 1 | 44 | St. Jude Children's Research HospitalOTHER | 1 | Jan 12, 2018 | clinicaltrials |
| NCT00854646 | Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS) | completed | Phase 1 | 22 | Traws Pharma, Inc.INDUSTRY | 1 | Jan 10, 2018 | clinicaltrials |
| NCT00541866 | Safety and Tolerability Study of Voreloxin and Cytarabine Combination in Acute Myeloid Leukemia in Humans | completed | Phase 1 / Phase 2 | 110 | Sunesis PharmaceuticalsINDUSTRY | 1 | Jan 9, 2018 | clinicaltrials |
| NCT01902329 | A Safety Study of SGN-CD33A in AML Patients | completed | Phase 1 | 195 | Seagen Inc.INDUSTRY | 1 | Jan 5, 2018 | clinicaltrials |
| NCT00303667 | Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant | completed | Phase 1 / Phase 2 | 50 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT02308761 | A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndrome | completed | Phase 1 | 26 | Hoffmann-La RocheINDUSTRY | 1 | Dec 11, 2017 | clinicaltrials |
| NCT02093403 | Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 25 | Bhavana BhatnagarOTHER | 1 | Dec 8, 2017 | clinicaltrials |
| NCT00556452 | Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen | completed | Phase 1 / Phase 2 | 46 | University of Michigan Rogel Cancer CenterOTHER | 1 | Dec 5, 2017 | clinicaltrials |
| NCT00686556 | Total Marrow Irradiation for Refractory Acute Leukemia | completed | Phase 1 | 12 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 5, 2017 | clinicaltrials |
| NCT00602693 | T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer | completed | Phase 1 | 41 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 2, 2017 | clinicaltrials |
| NCT00365287 | Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer | completed | Phase 1 / Phase 2 | 148 | Masonic Cancer Center, University of MinnesotaOTHER | 0 | Nov 29, 2017 | clinicaltrials |
| NCT01110473 | ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies | completed | Phase 1 | 52 | AbbVie (prior sponsor, Abbott)INDUSTRY | 1 | Nov 20, 2017 | clinicaltrials |
| NCT00466895 | Lenalidomide in Acute Leukemias and Chronic Lymphocytic Leukemia. | completed | Phase 1 | 37 | Leslie AndritsosOTHER | 1 | Nov 14, 2017 | clinicaltrials |
| NCT00903422 | Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS) | completed | Phase 1 | 98 | GlaxoSmithKlineINDUSTRY | 11 | Nov 13, 2017 | clinicaltrials |
| NCT01380756 | Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia | completed | Phase 1 | 35 | AmgenINDUSTRY | 1 | Nov 6, 2017 | clinicaltrials |
| NCT00301951 | Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer | completed | Phase 1 | 7 | University of California, San FranciscoOTHER | 1 | Oct 12, 2017 | clinicaltrials |
| NCT02270788 | Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies | completed | Phase 1 | 10 | St. Jude Children's Research HospitalOTHER | 1 | Oct 3, 2017 | clinicaltrials |
| NCT01449058 | A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors | completed | Phase 1 | 139 | Array BioPharmaINDUSTRY | 7 | Oct 2, 2017 | clinicaltrials |
| NCT00006239 | Phenylbutyrate and Tretinoin in Treating Patients With Hematologic Cancer | completed | Phase 1 | — | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 29, 2017 | clinicaltrials |
| NCT00245037 | Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer(Bu Flu TBI) | completed | Phase 1 / Phase 2 | 147 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 27, 2017 | clinicaltrials |
| NCT02544438 | Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia(BSTPHASE1-01) | completed | Phase 1 / Phase 2 | 20 | BioSight Ltd.INDUSTRY | 1 | Sep 27, 2017 | clinicaltrials |
| NCT01254578 | Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers | completed | Phase 1 | 17 | National Cancer Institute (NCI)NIH | 1 | Sep 25, 2017 | clinicaltrials |
| NCT01249430 | Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Sep 21, 2017 | clinicaltrials |
| NCT01399840 | Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies | completed | Phase 1 | 33 | PfizerINDUSTRY | 2 | Sep 15, 2017 | clinicaltrials |
| NCT00988715 | Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome | completed | Phase 1 | 17 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 30, 2017 | clinicaltrials |
| NCT01947322 | Haploidentical NK-cell Infusion in Acute Myeloid Leukemia(NK) | completed | Phase 1 / Phase 2 | 10 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Aug 29, 2017 | clinicaltrials |
| NCT00624936 | Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes | completed | Phase 1 | 23 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Aug 22, 2017 | clinicaltrials |
| NCT01169012 | PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias | completed | Phase 1 | 13 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Aug 22, 2017 | clinicaltrials |
| NCT01141725 | Bendamustine and Idarubicin in Treating Older Patients With Previously Untreated AML or MDS | completed | Phase 1 / Phase 2 | 39 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 18, 2017 | clinicaltrials |
| NCT01606579 | Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies | completed | Phase 1 / Phase 2 | 49 | Prism Pharma Co., Ltd.INDUSTRY | 1 | Aug 17, 2017 | clinicaltrials |
| NCT01048827 | Targeted, Dose-Escalation Busulfan-Etoposide as Prep Regimen(Busulfan) | completed | Phase 1 | 12 | University of California, San FranciscoOTHER | 1 | Aug 11, 2017 | clinicaltrials |
| NCT00702403 | Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML | completed | Phase 1 / Phase 2 | 40 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 10, 2017 | clinicaltrials |
| NCT01130506 | Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | completed | Phase 1 | 17 | National Cancer Institute (NCI)NIH | 1 | Aug 2, 2017 | clinicaltrials |
| NCT01961765 | Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 18 | Massachusetts General HospitalOTHER | 1 | Jul 21, 2017 | clinicaltrials |
| NCT00104923 | Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer | completed | Phase 1 | 29 | California Cancer ConsortiumNETWORK | 1 | Jul 19, 2017 | clinicaltrials |
| NCT00448357 | Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen(LCCC0510) | completed | Phase 1 / Phase 2 | 54 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jul 17, 2017 | clinicaltrials |
| NCT00839982 | Clofarabine and Cytarabine in Treating Older Patients With AML or High-Risk MDS | completed | Phase 1 / Phase 2 | 35 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 11, 2017 | clinicaltrials |
| NCT01677780 | An Extension Study of RO5045337 in Participants Participating in Previous Roche-sponsored Cancer Studies | completed | Phase 1 | 11 | Hoffmann-La RocheINDUSTRY | 3 | Jul 7, 2017 | clinicaltrials |
| NCT00270452 | Safety of Peptide Vaccination for Patients With Myelodysplastic Syndrome | completed | Phase 1 | 9 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00692926 | Unrelated Umbilical Cord Blood Transplantation Augmented With ALDHbr Umbilical Cord Blood Cells | completed | Phase 1 | 37 | Joanne Kurtzberg, MDOTHER | 1 | Jun 29, 2017 | clinicaltrials |
| NCT00854945 | Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML | completed | Phase 1 / Phase 2 | 36 | Traws Pharma, Inc.INDUSTRY | 1 | Jun 26, 2017 | clinicaltrials |
| NCT01167166 | Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL) | completed | Phase 1 / Phase 2 | 30 | Traws Pharma, Inc.INDUSTRY | 1 | Jun 26, 2017 | clinicaltrials |
| NCT00241358 | Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies | completed | Phase 1 / Phase 2 | 92 | Washington University School of MedicineOTHER | 1 | Jun 6, 2017 | clinicaltrials |
| NCT00513474 | Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant | completed | Phase 1 | 46 | Massachusetts General HospitalOTHER | 1 | May 25, 2017 | clinicaltrials |
| NCT01820624 | Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 12 | Paolo Caimi, MDOTHER | 1 | Apr 27, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Mar 9, 2018source: clinicaltrials